Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial

A phase II trial in advanced renal cell carcinoma (RCC) found no benefit in efficacy or safety between patients receiving oral sunitinib 50 mg/day for 4 weeks followed by 2-week off-treatment (Schedule 4/2) and those receiving 37.5 mg continuous daily sunitinib. We hypothesized that fatigue would ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Cella, David, Jensen, Sally E, Hahn, Elizabeth A, Beaumont, Jennifer L, Korytowsky, Beata, Bhattacharyya, Helen, Motzer, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302685/
https://www.ncbi.nlm.nih.gov/pubmed/25044922
http://dx.doi.org/10.1002/cam4.286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302685/
https://www.ncbi.nlm.nih.gov/pubmed/25044922
http://dx.doi.org/10.1002/cam4.286

Ejemplares similares